

ABN 64 055 747 941

Thursday 17 February, 2011

Company Announcements Office,
Australian Securities Exchange Limited
20 Bridge Street,
Sydney NSW 2000

MARKET UPDATE

Healthcare solutions company MediVac Limited [ASX: MDV] today releases the attached Market Update.

The presentation is being used in broker presentations to inform the investment community on the Company's progress in commercialising its key MetaMizer and SunnyWipes initiatives.

Recent achievements are highlighted on slides 6 & 7 of the presentation.

As these commercialisation activities are completed, the Company will be in a stronger position to execute new sales opportunities in the forthcoming periods.



Paul McPherson
Executive Chairman

About MediVac Limited: "MDV"

MediVac delivers cleaner, safer healthcare solutions.

MediVac Technology offers a best practice solution to the handling and remediation of clinical waste. The MetaMizer is an environmentally friendly alternative waste management system for hospitals and quarantine facilities, providing sterile, safe waste disposal on site and reducing waste to landfill by up to 90%.

SunnyWipes are a range of powerful hard surface wipes and hand sanitising gels produced with ingredients derived from natural sources. Using green chemistry, SunnyWipes provides a more natural solution for infection control and disinfection on topical skin and non porous hard surfaces. SunnyWipes decrease human and environmental health risks.

Media enquiries:

Richard Allen
Oxygen Financial Public Relations
Ph: 03 9915 6341

For personal use only



ASX Market Update
February 2011

Agenda

- ❖ Who are we?
- ❖ Our Mission
- ❖ Our businesses & “clean” credentials
- ❖ Recent achievements
- ❖ Medivac strategy
- ❖ Medivac Technology strategy
- ❖ SunnyWipes strategy
- ❖ Appendix – Director Information
- ❖ Appendix - Disclaimer

Our Mission



medivac
Cleaner, Safer, Healthcare Solutions

*Healthcare solutions that protect
people and the environment*

To build shareholder value by profitably developing & commercialising cleaner, safer healthcare solutions for Domestic and International markets.

Who are we ?

- ❖ Medivac Limited – ASX listed (since 2004) Public Company – operating in the healthcare industry
- ❖ Issued shares: 1,469,836,606 ordinary shares
- ❖ Market capitalisation: approx \$9 million
- ❖ 3 operating subsidiaries – Medivac Technology, SunnyWipes, Diakyne
- ❖ Final stages of transitioning from an R & D focussed company to currently commercialising Medivac Technology and SunnyWipes
- ❖ Strong focus on international markets

About MediVac



Two clean safe health care initiatives:

- ❖ The MetaMizer and Ozonator are best practice, environmentally friendly solutions to the remediation of bio hazardous waste for hospitals and quarantine facilities
- ❖ SunnyWipes is a more natural eco friendly range of antimicrobial hand sanitising gels and hard surface wipes that are both recyclable and compostable.

Recent achievements

- ❖ Near completion of the Company's 2 major commercialisation activities:
 - SunnyWipes Antimicrobial Gel and General Virucidal Wipes both now registered on the Therapeutic Goods Administration (TGA) register - – making SunnyWipes the World's first Type 1 Eco certified & professionally registered range
 - First new MM 240 SSS clinical waste converter will be completed in March

- ❖ MOU signed with Sri Lanka Ministry of Health for min. 25 (possibly 30) new MetaMizer 240 SSS clinical waste remediation devices – potential revenue of up to \$15 million. Final proposal to be submitted this month (February)

- ❖ Successful manufacturing trials & initial production run of new SunnyWipes Gel completed at GMP facility

Recent achievements (cont)

- ❖ The Company's key new product initiatives were launched to the international market at Medica in Dusseldorf Germany in November 2010
- ❖ MediVac Board strengthened with appointments of The Hon. Reba Meagher and Ms. Helen Owens, bringing strong healthcare and government experience
- ❖ Secured a \$20m equity funding facility with Boston (USA) based Dutchess Capital

Group Strategy

- ❖ Strong focus on completion of commercialisation of core Medivac Technology and SunnyWipes businesses
- ❖ Appoint international partners / alliances
- ❖ Build inventory to satisfy demand and sales pipeline
- ❖ Provide sufficient R&D resources between these businesses to leverage unique IP
- ❖ Rigid focus on cost containment
- ❖ Identify a partner to commercialise Diakyne



MetaMizer 240 SSS Biohazardous Waste Converter

Traditional “Truck & Treat”

Inefficient, environmentally unsound, problematic, OH&S issues and expensive!



The MediVac Process

Lower Cost

Lower Risk

Environmentally Friendly

HOSPITAL



CLINICAL
WASTE

SHARPS



HOSPITAL
GENERAL
WASTE
STREAM

- ❖ Related Waste
- ❖ Non-Disposable Instruments
 - Scissors, staple cartridges, hip joints, surgical screws etc.




Traditional "Truck & Treat"
Approx 1-2% Volume

Best practice solution to the handling and remediation of clinical waste

- ❖ Reduces the volume of waste to landfill by up to 90%
- ❖ No chemical treatment or incineration
- ❖ Improved infection control – 100 x UK standards
- ❖ Minimises the OH&S risks associated with the handling of clinical, sharps and infectious waste
- ❖ Sterilizes & granulates (simultaneously) clinical & sharps waste in 12 – 15 minutes
- ❖ Output is inert
- ❖ Accredited process
- ❖ Small footprint
- ❖ Process transferable to handling of quarantine waste
- ❖ Output could be recycled
- ❖ Distribution partners established for Japan, North America, Europe, Russia & CIS, Cyprus, Greece & India
- ❖ NATA & ISO Laboratory validated, Health Depts & EPA approved process
- ❖ Aichi World Expo, Global 100 Eco Tech Award in Japan
- ❖ ACHS awarded Cairns Hospital – 2005 Quality Improvement Award

New MetaMizer 240 SSS



NEW MM 240 Characteristics / Advantages

- ❖ High capacity – utilises 120 litre & 240 litre bins
- ❖ Can treat 32 x 240 l bins / 8 hour shift
- ❖ Round chamber – no corners for waste to stick
- ❖ Large outlet gate (8 inches)
- ❖ Pressure vessels will be constructed from 316 Stainless Steel – ASMI / Lloyds of London approved suppliers
- ❖ Potential for multi-lingual user interface
- ❖ Easy access to all data files for the site management, with an easy to access SD memory Card plugged into the PLC.
- ❖ Fully automated, remote controls – safety for operator
- ❖ Colourful and simple controls – easier operation
- ❖ Designed to be loaded into a shipping container for cheaper logistics

NEW MM 240 SSS Environmental Advantages

- ❖ Volume to landfill reduced by up to 90%
- ❖ No incineration
- ❖ No chemical treatment
- ❖ No CO2 / harmful emissions
- ❖ Low utility usage
 - 30 – 40kW per hour
 - 2.5 litres of water per cycle
- ❖ Reduced transport & storage requirements
- ❖ Small footprint – required area of 7m wide x 9 metres long x 3 metres high
- ❖ Output could be recycled

Summary - Benefits

- ❖ Cost Effective – significant savings for clinical & sharps waste disposal
- ❖ No Capital Investment – with leasing model for domestic markets
- ❖ Improved OH&S – increased safety in handling
- ❖ State of the Art – automated, high throughput sterilisation, 100 x International Standards
- ❖ System Change – assists with infection control (including sharps)
- ❖ No More Stored Waste – Odour eliminated on wards
- ❖ Risk reduction – mitigates “cradle to grave” legislation

The OZONATOR NG 1000



Ozone – a Proven Technology

- ❖ Ozone in use as sterilizing agent for over 100 years
- ❖ Kills all known pathogens - as one of nature's most effective and efficient bactericides and fungicides
- ❖ Does not promote resistance
- ❖ Proven operational safety and efficacy
- ❖ Leaves no residues
- ❖ OZONATOR technology provides 6 log¹⁰ reduction

OZONATOR Operational Advantages

- ❖ Improved infection control
- ❖ Improves quality of workplace – no odors or storage
- ❖ Improved safety
- ❖ Risk reduction in waste handling and storage
- ❖ Reduces carbon footprint
- ❖ Reduces harmful emissions dioxins et al
- ❖ Enhances landfill safety
- ❖ No harmful chemicals, noxious odors or corrosive liquids

Ozonator Performance Advantages

- ❖ Independent tests on OZONATOR technology show 6 log¹⁰ reduction
- ❖ Standard biological indicators used for regular testing and verification
- ❖ Fully compliant with U.S. and Canadian Occupational Health & Safety regulations
- ❖ Ozone converted back into oxygen in sealed environment
- ❖ No harmful emissions – No odours
- ❖ Complete tracking of all metrics with Internet reporting
- ❖ Built-in safety redundancies
- ❖ Automatic environmental sensing
- ❖ Emergency shut-down

Ozone's Environmental Advantages

- ❖ Ozone decomposes into oxygen
- ❖ No dioxin emissions (as incineration)
- ❖ No toxic ash (as incineration)
- ❖ No harmful chemicals
- ❖ No non-biodegradable packaging
- ❖ No lengthy high-risk transportation
- ❖ No exposure to liabilities

MediVac Technology Strategy

- ❖ Complete and test MetaMizer 240 SSS prototype
- ❖ Complete negotiations and secure Sri Lanka deal for 25 – 30 MM 240's devices
- ❖ Scale up production to build inventory of finished product & spares to satisfy demand
- ❖ Work with local waste companies to build local presence
- ❖ Leverage existing overseas distribution network and appoint partners
- ❖ Attack quarantine market & very high volume medical opportunities with Ozonator

MediVac Technology Opportunities

- ❖ World wide market estimated at US\$2 billion +
- ❖ Have signed Sri Lanka MOU for 25-30 new MM 240 SSS devices (\$15m potential)
- ❖ Strong interest from other overseas markets – especially developing countries
- ❖ Significant domestic opportunity – hospitals with 100 – 500 beds (167 hospitals)
- ❖ EPA restrictions on incinerators
- ❖ Tighter regulations on untreated waste going to landfill
- ❖ Partnering opportunities from logistics operators
- ❖ Limited competition
- ❖ Ozonator opportunities with major airports, ports and very large hospitals

For personal use only



medivac
Cleaner, Safer, Healthcare Solutions



Potential problems with current hygiene products

- ❖ Dry and cracked skin
- ❖ Contact Dermatitis
- ❖ Need for a separate moisturizer
- ❖ Sore red raw hands
- ❖ Eczema
- ❖ Itchy Skin
- ❖ Skin Allergy
- ❖ An unwillingness to use
- ❖ Leaves a residual fragrance
- ❖ Leaves tacky residuals

SunnyWipes Uniqueness

- ❖ Produced from natural ingredients – using green chemistry
- ❖ Eucalyptus oil & ethanol from natural sources
- ❖ Registered on the Therapeutic Goods Australia (TGA) register
- ❖ World's first Type 1Eco certified & professionally registered range
- ❖ Non hazardous synthetic chemical derivatives
- ❖ High powerful infection control properties
- ❖ Derived from sustainable plantations & renewable resources
- ❖ Solutions are a non primary source of Irritancy or sensitisation on human skin
- ❖ Chemicals that do not bio-accumulate
- ❖ Packaging is recyclable and compostable
- ❖ Complies to WHO standards
- ❖ Clear point of environmental difference – GECA endorsed
- ❖ Multiple applications & Market segments
- ❖ Australian owned ASX listed Company

For personal use only




Antimicrobial Hand Sanitising Gels

Tested Against World standards that are Engineered to deliver!

- ❖ Antimicrobial strength
- ❖ Antimicrobial activity time kill MRSA & VRE 30 seconds 99.99% 4 Log reduction
- ❖ Registered on the Therapeutic Goods Australia (TGA) register – Aust. R 172237
- ❖ Complies to EN 1500 hand rub 3.98 Log reduction
- ❖ Passed EN 12791 surgical Handrub study
- ❖ Passed a broad spectrum antibacterial study battery
- ❖ Twin system – sanitises & moisturises skin to help protect skin integrity
- ❖ Log kill 3.0 ROTOVIRUS
- ❖ 1.26 Log reduction C. Difficile 94.5 % kill
- ❖ 3 Log reduction Tinea fungi strains 99.9% kill
- ❖ Dermatologically tested non primary skin irritant or sensitiser
- ❖ Kills 99.99% general bacteria 30 seconds
- ❖ Leave on Application - no need to rinse or wash off residuals
- ❖ TGA disinfectant test Option D passed skin antiseptics study
- ❖ Complies to WHO “5 Moments of Hand Hygiene”

For personal use only



General Virucidal & Antimicrobial Hard Surface Wipes

- ❖ 70% Ethanol kills germs fast
- ❖ Naturally derived formulation
- ❖ Registered on the Therapeutic Goods Australia (TGA) register – Aust. R 178629
- ❖ Kills Type A Influenza viruses
- ❖ Hospital Grade Disinfection
- ❖ Kills 99.99% germs including MRSA and VRE staph bacteria fast
- ❖ HACCP endorsed
- ❖ Good Environmental Choice Australia (GECA) endorsed
- ❖ Recyclable packaging green procurement
- ❖ Kills Polio
- ❖ Kills Andeneo
- ❖ Kills Herpes simplex
- ❖ Kills bacteria

SunnyWipes Endorsements



SUN-2009
GECA 06-2007 –
Personal Care Products

Good Environmental Choice Australia (GECA)



HACCP Australia Accreditation (Wipes)



Signatory to Compact for Safe Cosmetics



CE Certification

Unsurpassed Features of Our Gels and Wipes

Features	Gels	Wipes
No harmful chemicals - No need to wear gloves - mask - or eyewear unless work policy	N/A	✓
Dermatologically tested . Non primary skin irritant - Non primary skin sensitiser	✓	✓
Kills 99.998% Germs	✓	✓
Hospital Grade efficacy TGA registered products	✓	✓
Non- skin irritant	✓	✓
Leave on - no need to wash off.	✓	✓
Good Environment Choice product	✓	✓
Contains a natural fresh eucalyptus smell	✓	✓
Synthetic Fragrance, preservative, detergent and colour free	✓	✓
100% recyclable	✓	✓
Totally "Green" product	✓	✓
Signatory to the safe cosmetic compact in USA	✓	✓
Kills 99.998% Germs including MRSA and VRE bacteria fast	N/A	✓
HACCP endorsed	T, R Δ	✓
Non carcinogenic substances when used according to instructions	✓	✓
Formulated using substances found in nature and using green chemistry	✓	✓
A hand sanitiser that is medically and scientifically proven to kill germs moisturise the skin and be used by all professionals and the general public	✓	N/A
Fast Acting	✓	✓
Proven not to cause Dry Cracked Skin (3) or Skin De-Hydration (4)	✓	N/A
Proven not to cause Dermatitis (2)	✓	✓

SunnyWipes Strategy

- ❖ With TGA registrations completed, urgently establish distribution in the key domestic healthcare channels
- ❖ Conduct clinical trials amongst Healthcare Workers to build endorsements
- ❖ Expand internationally thru distributors in North America & Europe
- ❖ Explore OEM and licensed manufacturing options
- ❖ Leverage unique IP thru range extension

SunnyWipes Opportunities

- ❖ Market for infection control products in excess of US\$3 billion.
- ❖ Growing global market for hand hygiene products
- ❖ Strong demand for “Green” products
- ❖ Licensed manufacturing
- ❖ OEM Branding
- ❖ Patents Protected
- ❖ Leverage unique IP and TGA approvals

Appendix - Director Information

❖ **Paul McPherson – B.Com., LLB, FAICD – (Executive Chairman)**

Paul McPherson was appointed as a Non Executive Director of MediVac on August 14, 2006. Mr. McPherson brings extensive experience in senior strategy development and implementation roles – Marketing, Sales, Commercial and General Management – with blue chip corporations such as Mars Inc, Bowater, Inchcape & Arnott’s. He has had hands on experience in Australia / New Zealand, Europe, Japan, and Asian markets. Mr. McPherson has run his own consultancy practice – PDM Solutions Pty Ltd – which specializes in assignments in strategy formulation and planning, Board effectiveness, business alignment and performance management. He has undertaken major consulting and facilitation projects in Australia, Japan & Asia Pacific. Mr. McPherson has worked and consulted in a diverse range of industries including food / non-food FMCG, wine / liquor, consumer electronics, importing / exporting and facilities management. Mr. McPherson holds a Bachelor of Laws and a Bachelor of Commerce (Accounting, Finance & Systems) from the University of New South Wales and has also completed the AICD Company Directors’ course. Mr. McPherson is a fellow of the Australian Institute of Company Directors (FAICD).

❖ **John Evans B.Com (Hons), CA ASA MAICD (Independent Non Executive Director)**

John Evans joined the Board of MediVac on December 3, 2007. Mr. Evans is a qualified Chartered Accountant and currently the principal of a Business Advisory practice. John advises a range of businesses in both the SME sector and larger corporate clients, on matters such as strategic planning, marketing, governance, and financial analysis. Prior to this, John held a series of positions in Finance and General Management over a 15 year period, across a wide range of industries including telecommunications, banking and insurance, superannuation and funds management, media, hospitality, and property development. John’s approach to advising businesses balances the need for practical, achievable solutions with the need to always keep in sight the overall strategic objective. John is a Member of the Australian Institute of Company Directors, a director of HealthLinx Limited, a director of two unlisted companies and a not-for-profit community leadership organisation, and provides Board consulting services to three other company groups.

Appendix - Director Information

❖ **Hon. Reba Meagher BA MLLR GAICD (Independent Non Executive Director)**

Reba Meagher joined the Board of MediVac on February 2, 2011. Ms Meagher is currently the Chief Executive Officer of the Sisters of Charity Foundation. The Foundation's purpose is to support works and programs that benefit the poor and marginalised in the community. Ms Meagher was a Member of the NSW Parliament from 1994-2008 and served as a Cabinet Minister for more than five years. She ran several portfolios including Health, Community Services, Aboriginal Affairs, Fair Trading and Commerce. Ms Meagher has a Bachelor of Arts and a Masters of Labour Law and Relations from the University of Sydney and was recently awarded the Diploma by the Australian Institute of Company Directors.

❖ **Helen Owens B.Ec (Hons), M.Ec (Independent Non Executive Director)**

Helen Owens joined the Board of MediVac on February 1, 2011. Ms Owens is an economist with extensive experience in the health sector. She is currently a member of the Victorian Southern Health Network Board and the Victorian Cancer Agency. She provides health consulting services, both individually and in association with accounting firm PricewaterhouseCoopers, to a range of clients including Commonwealth and state governments. Ms Owens' previous roles include Commissioner, Productivity Commission (1993 to 2006) and member, Commonwealth Grants Commission (2004 to 2006). In the former position she directed major national inquiries and research across many sectors of the Australian economy on behalf of the Commonwealth Government, including into Research and Development in Australia, the pharmaceuticals industry, the medical and scientific equipment industries, private health insurance, general practice, and advances in new medical technologies. Ms Owens was expert strategic consultant to the Victorian government on national health reform for five years from 2005. Ms Owens has sat on the CSIRO Health Sector Advisory Council, Australian Health Technology Advisory Committee, Economics Sub-Committee of the PBAC, and Royal Melbourne Hospital boards. Ms Owens is a recipient of the Centenary Medal for services to Australian Society and the Economy.

Appendix - Director Information

❖ **Peter Steve (Executive Director – Research & Development)**

Peter Steve joined the Board of MediVAc on October 30, 2008. Mr. Steve is the Inventor of the SunnyWipes products and company founder. As an Executive Director of MediVac Limited and as the Research & Development Manger of SunnyWipes, Peter’s responsibilities include ongoing research and development, IP issues, and regulatory/compliance matters. Prior to founding SunnyWipes, Mr. Steve worked in meat retailing. As well as owning his own retail outlets, Peter held senior management positions in a large supermarket chain and had also been the National Training & Marketing Manager for Angliss Retail Pacific. Peter also has accreditations in Business and Training management.

❖ **Mal Lucas-Smith (Company Secretary)**

Mr. Lucas-Smith was appointed Company Secretary of Medivac Limited on 3 December 2007. He has had over 40 years experience in finance, executive and non executive management, property development, corporate secretarial and administrative services. During that period he spent 12 years with State Bank of New South Wales and 18 years with the property finance and the property joint venture divisions of Australian Guarantee Corporation Limited, at the time a listed subsidiary of Westpac Bank. He left AGC of his own accord in September 1987 to form a corporate services business and has since worked within and consulted to the corporate sector often assisting new start ups and existing operations proposing to list on the ASX. Mr. Lucas-Smith is a member of the Australian Institute of Company Directors (MAICD).

Appendix - Disclaimer

DISCLAIMER

This Power Point summary ("PP") is not an offer, invitation or recommendation to any recipient or to any other persons to subscribe for securities in the Company and simply sets out information to allow potential investors to consider and evaluate the merits of the various businesses that comprise the Company. To the extent it is included with, or taken to be, an offer of the securities in the Company, it is only an offer, and may only be taken to be an offer, in the circumstances where, pursuant to Section 708 of the Corporations Act 2001, a disclosure document is not required. No steps have been taken for the lawful receipt or distribution of this ES in any jurisdiction outside Australia.

RESPONSIBILITY

The Company is the issuer of this PP. Neither the Company nor its advisers have independently verified any of the information contained in the PP, including any forecast or projected information and any assumptions upon which those statements are based.

None of the Company or its Directors:

- make (and will not make) any representation or warranty (express or implied) regarding; or
- accept (and will not accept) any responsibility or liability (including negligence) for, the truth, accuracy or completeness of any statement, opinion, forecast, information or other matter (whether expressed or implied) in this PP.

None of the Company or its Directors, have (and will not have) any responsibility or liability (including in negligence):

- for, or in connection with, any act or omission directly or indirectly in reliance upon; or
- for any expense, loss or other liability directly or indirectly arising from, or in connection with, any omission from or defects in, or any failure to correct any information in this PP or any other communication (written or oral) about or concerning the Company, and/or the issue of shares in the Company.

This PP includes certain statements with respect to the Company's future operations and performance. Such statements reflect various assumptions made by the Directors of the Company concerning, or which are relevant to, the anticipated operations of the Company. Those assumptions and/or anticipated operations of the Company are and will be subject to uncertainties and contingencies many, if not all, of which are outside the control of the Company. Therefore, those assumptions and/or anticipated returns may or may not prove to be correct or valid. While the statements and estimates made by the Company and contained in this PP genuinely represent the views of the persons to whom they are attributed, they involve subjective judgement and analysis that may or may not be correct. No representations or warranties are (or will be made), and no responsibility or liability (including in negligence) is (or will be) accepted by the Company or the Directors as to the truth, accuracy or completeness of such statements, assumptions or estimations or projections (and no such representations or warranties should be inferred).